Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Arctic Bioscience – PIR IV INVEST to distribute shares in Arctic Bioscience to fund investors

PIR IV INVEST AS (“PIR IV”), an early stage investment SPV and major shareholder in Arctic Bioscience AS ("Arctic Bioscience"), today announced the planned dissolvement of the SPV. As a consequence, its shares in Artic Bioscience will be re-allocated to the SPV’s individual investors. PIR IV holds 2,188,250 million shares in Arctic Bioscience, corresponding to 9.0% of total shares outstanding.In connection with the IPO of Arctic Bioscience, PIR IV entered into a customary lock-up agreement to remain in force to and including 365 calendar days after the date of admission to trading on

Enzymatica and STADA extend agreement on ViruProtect to Vietnam

Enzymatica has licensed to STADA exclusive rights to market and sell ViruProtect® (ColdZyme®) in Vietnam. The agreement builds on the two companies’ existing successful partnership to market ViruProtect, a medical device for treating and alleviating common colds, in approximately 40 countries worldwide. Extending the partnership will leverage Enyzmatica’s technological expertise with STADA’s substantial commercial footprint and sales and marketing infrastructure in Vietnam through its STADA Vietnam and Pymepharco subsidiaries.Enzymatica AB and STADA are expanding their successful commercial

Invitation to Rottneros interim report, Q2 2021

The interim report for the second quarter 2021 will be published on July 22 2021, 8.00 CET, and is followed by a webcast live at 13.00 CET the same day.All participants can follow the presentation via the web link: https://www.finwire.tv/webcast/rottneros/q2/  Questions can be asked via the link in advance or during the presentation.You can also watch the presentation afterwards via Rottneros'  Youtube channel and website: https://www.rottneros.com/investors/presentations/

Addtech´s 2020/2021 Annual Report is now published

The Annual Report describes Addtech’s mission, vision, strategy, and operations as well as the results and value created. It also contains a report on corporate governance, which is integrated in the annual report. The Sustainability reporting is also partially integrated within the Annual report. The annual report can be read directly online or be downloaded as a PDF file, both at www.addtech.com The printed version will be distributed to all who have ordered it in late July. Stockholm, 12 July 2021 Addtech AB (publ) For more information, please contactMalin Enarson, CFO,

Buybacks of shares in Alfa Laval during week 27 2021

During the period July 5 – July 9, 2021, Alfa Laval AB (publ) (LEI code: 549300UCKT2UK88AG251) has repurchased in total 123,923 own shares (ISIN: SE0000695876) as part of the share buyback program initiated by the Board of Directors in order to secure optimized capital structure.The share buybacks form part of the SEK 2 billion share buyback program, which Alfa Laval announced on April 27, 2021. The share buy-back program, which runs between April 28, 2021 and April 25, 2022, is being carried out in accordance with the EU Market Abuse Regulation (MAR) and the Commission Delegated Regulation

Invitation to presentation in connection with EQL Pharma's quarterly report, first quarter, 2021/22

EQL Pharma AB (publ) will publish its quarterly report for the first quarter, 2021/22, on Monday, August 16[th], after stock markets closing At 10.00 (CET) 17[th] August, the company will give a presentation via video conference. The presentation is aimed at shareholders and potential shareholders. President and CEO Christer Fåhraeus presents and comments on the quarterly report. After the presentation, there is an opportunity to ask questions for those who participate.Use the following link to access the virtual meeting: https://tinyurl.com/rbtdef8b Date and time August 17[th],

Lundin Gold Delivers Another Quarter of Strong Production

108,799 OUNCES OF GOLD PRODUCED IN THE SECOND QUARTER OF 2021VANCOUVER, BC, July 12,2021 /CNW/ - Lundin Gold Inc. (TSX: LUG; Nasdaq Stockholm: LUG) ("Lundin Gold" or the "Company") is pleased to report second quarter 2021 gold production of 108,799 ounces (“oz”) from its Fruta del Norte gold mine (“Fruta del Norte”) in southeast Ecuador. Of the total gold production, 66,721 oz were produced as a concentrate and 42,078 oz as doré. During the second quarter of 2021, the mill processed approximately 346,561 tonnes at an average throughput rate of 3,808 tonnes per day, the average grade of

FLNG – Repurchase of shares

July 12, 2021Hamilton, Bermuda Flex LNG Ltd. (“Flex LNG” or the “Company”) announces that the Company has during the period between July 7 and July 9, 2021, purchased 66,694 of the Company’s own common stocks. The shares have been bought on the Oslo Stock Exchange at an average price of NOK 120.86 per share. Following the completion of the above transactions, Flex LNG owns a total of 894,038 of own shares, corresponding to 1.65% of the Company’s share capital. The transaction is part of the share buyback program announced on November 19, 2020. An overview of all transactions made

BERGENBIO PRESENTS ENCOURAGING COMBINED DATA FOR BEMCENTINIB FROM TWO PHASE II COVID-19 STUDIES AT ECCMID

· Survival 96.6% vs 91.2% · Significantly reduced likelihood (69%) of progression to ventilation in higher severity cohort · Significantly increased likelihood (88%) of shorter time to recovery or discharge in higher severity cohort · Clinical evidence of anti-viral mechanism of action · Preclinical analysis highlights bemcentinib’s potential against COVID-19 variants Bergen, Norway, 12 July 2021 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, has presented a combined

BioStock: Aptahem’s CEO looks forward to an exciting second half of the year

During 2021, sepsis company Aptahem has taken several steps to prepare for its first clinical evaluation of its leading drug candidate Apta-1. Ahead of the phase I studies that are expected to begin next year, the company has so far this year received the preliminary approval of patents pertaining to family two in Europe and the USA. Together with Örebro University, the company has also identified a mechanism of action has at the molecular level for the drug candidate. BioStock spoke with CEO Mikael Lindstam about the past six months and what he expects from the second half of the year.Read

Sober Grid Users to Gain Access to Clinically Proven Digital Therapeutics Through New Commercial Partnership with Orexo

The digital therapeutics, which help manage problematic alcohol use and depression through a cognitive behavioral therapy-based approach, will be available to the Sober Grid community beginning August 2021.MORRISTOWN, N.J. July 12, 2021 – Sober Grid, the largest social media network for those in addiction recovery, and Orexo, a Swedish pharmaceutical company, today announced that Sober Grid’s more than 300,000 users will gain access to Orexo’s clinically proven digital therapeutics for problematic alcohol use (vorvida®) and depression (deprexis®) through their new partnership. The Sober

Hexagon Purus receives orders from leading gas distributor to deliver hydrogen cylinders for industrial and mobility applications in Europe

Hexagon Purus has received new orders from a leading gas distributor to deliver Type 4 hydrogen cylinders for industrial and mobility applications. The orders have a value of approximately EUR 2 million (approx. NOK 20 million). Hexagon Purus’ Type 4 cylinders will be part of storage and transportation solutions that will transport hydrogen for industrial purposes and expand the infrastructure for hydrogen mobility projects in Europe. Driving energy transformation“As the push for the energy transition continues, we are proud to see that our Type 4 tank technology can enable our

Invitation to presentation of 2nd quarter 2021 results

In connection with the release of the 2nd quarter 2021 results, Bonheur ASA will publish its 2Q 2021 report on Wednesday 14 July at 09:00 CET. Consequent on the Covid-19 pandemic the presentation will be held by way of a webcast. To listen to the presentation and ask questions via telephone, please register online to receive your personal PIN and number with this link: http://emea.directeventreg.com/registration/5465357 To watch presentation in a webcast, use this link: https://edge.media-server.com/mmc/p/zqipctjp Note: Due to regional restrictions some participants may receive

Brighter's Subsidiary Nectarine Health Receives Approval to Release Nectarine Health™ Customer Interface App

Brighter AB (publ) announced today that the company’s subsidiary Nectarine Health received approval from Apple and Google for its consumer app, an integral part of the company’s remote home care solution. Nectarine Health™ at Home utilizes the app to give wristband wearers and their carers access to wellbeing insights and manage alerts such as hard falls. The app is now available to download in the U.S. via the AppStore and PlayStore. “This approval marks another significant milestone for Nectarine Health as we start to commercialize our product. We currently remain on track with our

CLS and Toronto General Hospital Resume Clinical Trial for Prostate Cancer as Company Receives Approval for Updated Sterilization Process by Health Canada

Lund, Sweden, 12 July, 2021 - Clinical Laserthermia Systems AB (publ) (CLS) , developer of high precision, image-guided focal laser ablation systems, today announced it has received approval from Health Canada for its updated sterilization documentation as well as an acceptance for its new sterilization supplier, ROSE GmbH. This means that CLS and University Health Network , that includes Toronto General Hospital in Toronto, Canada, can now resume the clinical Phase II trial, led by Dr. Sangeet Ghai, regarding MRI-

CLS and Toronto General Hospital Resume Clinical Trial for Prostate Cancer as Company Receives Approval for Updated Sterilization Process by Health Canada

Lund, Sweden, 12 July, 2021 - Clinical Laserthermia Systems AB (publ) (CLS) , developer of high precision, image-guided focal laser ablation systems, today announced it has received approval from Health Canada for its updated sterilization documentation as well as an acceptance for its new sterilization supplier, ROSE GmbH. This means that CLS and University Health Network , that includes Toronto General Hospital in Toronto, Canada, can now resume the clinical Phase II trial, led by Dr. Sangeet Ghai, regarding MRI-

Investor Letter July 2021

Ingemar Kihlström, Chairman of the Board, and Johan Folkunger, CEO, reflect on a strong commitment and combined expertise and Homer Pien, recently appointed Board member of SpectraCure, is introduced.Investor letter July 2021 is attached.  For further information, please contact:Johan Folkunger, SpectraCures CEO, e-mail: jf@spectracure.comPlease also visit, www.spectracure.comSpectraCure is developing a treatment system for the elimination of internal solid cancer tumors. We are initially focusing on recurrent prostate cancer. The hope is to be able to treat other cancers such as

Interim Report January - June 2021

APRIL − JUNE 2021 · Net sales increased by 30.3 % to SEK 1,488 million (1,142) · Operating profit amounted to SEK 38 million (34) · Profit after financial items amounted to SEK 16 million (7) · Profit after tax amounted to SEK 9 million (4) · Earnings per share amounted to SEK 0.03 (0.04) · Cash flow from operating activities amounted to SEK -158 million (257) In 2021, non-recurring items impacted the profit after financial items by SEK -43 million (-30). · EBITDA excluding non-recurring items amounted to SEK 144 million (128) · Net debt amounted to SEK 1,

Invitation to Noreco Second Quarter 2021 Earnings Call

Norwegian Energy Company ASA ("Noreco" or "the Company") will publish its financial results for the second quarter of 2021 on Tuesday 13 July 2021 at 07:00 (CEST).  An earnings call, available as an audiocast, will be hosted at 12:00 (CEST).To join earnings call: https://channel.royalcast.com/hegnarmedia/#!/hegnarmedia/20210713_2   ***   Contact:Cathrine Torgersen, EVP Investor Relations & CommunicationsEmail: ct@noreco.com

AEA Investors acquires Polygon from Triton

Funds advised by Triton Partners (“Triton”) have signed an agreement to sell Polygon Holding AB (“Polygon”) to funds managed by AEA Investors LP (“AEA”). AEA, together with the management team, will acquire 100 percent ownership of Polygon. Closing of the transaction is subject to customary regulatory approvals and is expected to occur in Q4 2021.Since the carve out from Munters and acquisition by Triton in 2010, Polygon has executed on its strategy of preventing, controlling and mitigating the effects of water, fire and climate for its customers. Today, Polygon is a leading property damage

Bambuser Enters Into Multiple New Agreements Totalling $2.2 Million

Stockholm — 12 July 2021 — Bambuser today announced that its wholly-owned subsidiary Relatable – a Bambuser company (“Relatable”) has entered into multiple new agreements for the provision of creative influencer marketing services. The agreements, signed with an American multinational computer software company and a European pharmaceutical company specializing in dermatological treatments and skin care products, have a total contract value exceeding $2.2 million (approx SEK 19 million).  Under terms of the agreement with the computer software company, Relatable will provide creative

Absolicon signed for a Pilot Solar collector field with Carlsberg Group in Greece

Absolicon is planning a pilot solar collector field with Carlsberg Group at the Olympic brewery in Sindos production site, Greece. The collector field, to be installed in early 2022, will be built with patented Absolicon T160 Solar collectors to run industrial brewing processes providing the energy needs related to the production through a heat purchase agreement.Absolicon and Carlsberg Group signed a deal to install in early 2022 a pilot solar collector field at Olympic brewery in Sidons plant in Greece. Absolicon is providing solar collectors and integration with a value of about 200 000€

Industrial Solar awarded grant for R&D project in the field of Artificial Intelligence

Clean Industry Solutions Holding Europe AB (ClSH) joins the ranks of companies leading the fourth industrial revolution under Artificial Intelligence (AI) banners, as its subsidiary company, Industrial Solar GmbH, has successfully been awarded a grant of total € 76,565 by the Ministry of Economic Affairs, Labor and Tourism of the state of Baden-Württemberg to optimize the performance and reliability of its concentrating solar technology.Today, Industrial Solar, a turnkey provider for customized renewable energy solutions, received the approval of its application for the AI innovation

Invitation to presentation of Komplett’s second quarter 2021 results, Thursday 22 July

Oslo, 8 July 2021: Komplett ASA will report its second quarter 2021 results on Thursday, 22 July 2021.CEO Lars Olav Olaussen and CFO Krister Pedersen will present the results at 08:00 CEST.The presentation will be sent via live webcast. Please use the following link to register and view the webcast: https://events.webcast.no/viewer-registration/3kBysTKC/register. The link will also be available on https://www.komplettgroup.com/investor-relations/. Questions to the speakers can be directed using the Q&A-tool embedded in the webcast and will be addressed towards the end of the

There are no items matching the current filter
There are no more items matching the current filter
Back to top